| Upgrades | Hold Buy | X | ||
|
$720 $992 |
||||
| Downgrades | Buy Hold | X | ||
|
$953 $720 |
||||
| Reiterated | Hold | X | ||
|
$408 $353 |
||||
| Reiterated | Hold | X | ||
|
$356 $304 |
||||
| Downgrades | Buy Hold | X | ||
|
$522 $356 |
||||
REGN Regeneron Pharmaceuticals, Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
